本帖最后由 老马 于 2013-3-13 13:43 编辑
/ O! B) D4 o5 R$ H- Y" A9 X& U$ W3 `& i1 h4 P, b/ q
健择（吉西他滨）+顺铂+阿瓦斯汀7 Y# v! v; s1 K
Gemzar +Cisplatin + Avastin6 X9 L2 `2 }0 v+ [% |! y
http://annonc.oxfordjournals.org/content/21/9/1804.full6 D' `0 @" W/ _9 o6 P# e
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) + b7 s/ E( r7 O1 p: I! S. A; F
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 9 H" J* P; n3 m6 O
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. # b& y( ^, v' P) ~$ B
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 898)
; c) E. p) g$ a g3 w( j$ z/ g
华为网盘附件：) n+ o3 a3 U" ^$ V. q$ D) q
【华为网盘】ava.JPG5 F! a& G- a6 g: _% [6 |
|
显身卡
